Nebraska is currently home to 726 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Omaha, Lincoln, Kearney and Grand Island. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Pompe Disease Registry Protocol
NCT00231400
Recruiting
The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both treated and not. Data from the Registry are also used to fulfill various global regulatory commitments, to support product development/reimbursement, and for other research and non-research related purposes. The objectives of the Registry are: * To enhance understanding of t... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/06/2025
Locations: University of Nebraska Medical Center- Pediatrics- Site Number : 840084, Omaha, Nebraska
Conditions: Glycogen Storage Disease Type II, Pompe Disease
Register for Updates
A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age
NCT07117487
Recruiting
The purpose of this study is to evaluate safety, tolerability and immunogenicity of mRNA-1345 in participants who have been previously vaccinated with either Arexvy or Abrysvo at least 12 months prior to enrollment, are medically stable and aged ≥60 years.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
08/05/2025
Locations: Velocity Clinical Research, Lincoln, Lincoln, Nebraska
Conditions: Respiratory Syncytial Virus
Register for Updates
A Study to Learn About How a New Pneumococcal Vaccine Works in Adults
NCT07086677
Recruiting
The purpose of this study is to learn about the safety and tolerability of a pneumococcal vaccine in adults. Participants will receive either: * an experimental PG4 vaccine * a PG4 vaccine comparator * a standard 20vPnC vaccine comparator * placebo. A placebo does not have any medicine in it but looks just like the study medicine. Participants will take part in this study for up to 18 months depending on which group they are assigned to. During this time, the participants will receive up to t... Read More
Gender:
ALL
Ages:
Between 65 years and 84 years
Trial Updated:
08/05/2025
Locations: Velocity Clinical Research, Omaha, Omaha, Nebraska
Conditions: Streptococcus Pneumoniae
Register for Updates
Group Activities to Support Addiction Recovery
NCT07071883
Recruiting
The purpose of this study is to pilot the use of Holotropic Breathwork (HB) for individuals seeking to recover from addiction. The study will have two arms: A--for individuals in residential treatment programs, B--for individuals living in the community. Arm A will use a cluster randomized intervention, providing HB for individuals at two facilities and a Multiple Modality (MM) intervention (yoga, meditation, and a film/discussion) at a third facility. In Arm B, we seek to measure the feasibilit... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
08/05/2025
Locations: University of Nebraska Medical Center, Lincoln, Nebraska
Conditions: Addiction, Substance Use Disorders (SUD)
Register for Updates
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
NCT06866405
Recruiting
This study aims to check how safe and well-tolerated a second dose of RSVpreF is when given during later pregnancies, and to see how long the immunity lasts from a single dose given during a previous pregnancy by examining the blood of nonpregnant participants who had the vaccine before.
Gender:
ALL
Ages:
0 years and above
Trial Updated:
08/05/2025
Locations: Velocity Clinical Research, Grand Island, Grand Island, Nebraska
Conditions: RSV Infection
Register for Updates
Abbott Medical - VERITAS Study
NCT06707688
Recruiting
The primary objective of this study is to evaluate the safety and effectiveness of Abbott's Amulet™ 2 Left Atrial Appendage (LAA) occluder device (Amulet 2 device) in patients who have non-valvular atrial fibrillation and who are at increased risk for stroke and systemic embolism and have appropriate rationale to seek a non-pharmacologic alternative to oral anticoagulation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: CHI Health Creighton University Medical Center-Bergan Mercy, Omaha, Nebraska
Conditions: Atrial Fibrillation (AF), Stoke
Register for Updates
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457
Recruiting
This study is open to adults who are at least 18 years old and have: * A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or * A confirmed liver disease called metabolic-associated steatohepatitis (MASH) * BMI of 27 kg/m2 or more or * 25 kg/m2 or more if the participant is Asian. People with a history of other chronic liver diseases or high alcohol intake cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps peop... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Metabolic Dysfunction Associated Steatohepatitis
Register for Updates
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
NCT06629779
Recruiting
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: Adult & Pediatric Urology, PC, Omaha, Nebraska
Conditions: Metastatic Castration-Resistant Prostate Cancer
Register for Updates
A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine
NCT06619509
Recruiting
This study is open to adults who participated in a previous clinical study with brigimadlin. The goal of this study is to find out how well people with solid tumours tolerate long-term treatment with brigimadlin. Brigimadlin is a so-called MDM2 inhibitor that is being developed to treat cancer. Participants are grouped in cohorts depending on their treatment in the previous study: * Cohort 1a got brigimadlin and continues treatment with brigimadlin * Cohort 1b got brigimadlin for 4 or less tr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: Nebraska Cancer Specialists-Omaha-69066, Omaha, Nebraska
Conditions: Solid Tumours
Register for Updates
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
NCT06492616
Recruiting
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: NHO Revive Research Institute LLC, Lincoln, Nebraska
Conditions: Breast Cancer
Register for Updates
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
NCT05918861
Recruiting
This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. A separate informed consent will be allowed for an initial pre-screening genetic testing. Subjects meeting the AA genotype will then consent to the full study and confirmatory genetic testing as required. Subject enrollment may... Read More
Gender:
ALL
Ages:
45 years and above
Trial Updated:
08/05/2025
Locations: Research Site, Lincoln, Nebraska
Conditions: Acute Coronary Syndrome
Register for Updates
A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma
NCT05850234
Recruiting
This trial is a phase 1b/2, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple Myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: Research Site, Omaha, Nebraska
Conditions: Relapsed/ Refractory Multiple Myeloma
Register for Updates